Sarepta Therapeutics Stock Price, News & Analysis (NASDAQ:SRPT)

$65.65 3.27 (5.24 %)
(As of 01/23/2018 02:51 PM ET)
Previous Close$62.38
Today's Range$63.01 - $66.08
52-Week Range$26.26 - $66.08
Volume2.35 million shs
Average Volume2.13 million shs
Market Capitalization$4.33 billion
P/E Ratio-32.18
Dividend YieldN/A
Beta1.37

About Sarepta Therapeutics (NASDAQ:SRPT)

Sarepta Therapeutics logoSarepta Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD). It is focused on the development of its disease-modifying DMD drug candidates. It has received accelerated approval for its product, EXONDYS 51, indicated for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping. EXONDYS 51 is studied in clinical trials under the name of eteplirsen. Its next generation phosphorodiamidate morpholino oligomer (PMO)-based compounds are synthetic compounds that bind to complementary sequences of RNA by standard Watson-Crick nucleobase pairing. Its PMO-based chemistries are peptide conjugated PMO (PPMO), PMO-X and PMOplus.

Receive SRPT News and Ratings via Email

Sign-up to receive the latest news and ratings for SRPT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:SRPT
CUSIPN/A
Phone+1-617-2744000

Debt

Debt-to-Equity Ratio0.04%
Current Ratio10.44%
Quick Ratio9.52%

Price-To-Earnings

Trailing P/E Ratio-32.1813725490196
Forward P/E Ratio-21.38
P/E GrowthN/A

Sales & Book Value

Annual Sales$5.42 million
Price / Sales782.83
Cash FlowN/A
Price / CashN/A
Book Value$6.17 per share
Price / Book10.64

Profitability

Trailing EPS($2.04)
Net Income$-267,260,000.00
Net Margins-112.08%
Return on Equity-51.72%
Return on Assets-43.55%

Miscellaneous

Employees197
Outstanding Shares64,630,000

Sarepta Therapeutics (NASDAQ:SRPT) Frequently Asked Questions

What is Sarepta Therapeutics' stock symbol?

Sarepta Therapeutics trades on the NASDAQ under the ticker symbol "SRPT."

How were Sarepta Therapeutics' earnings last quarter?

Sarepta Therapeutics Inc (NASDAQ:SRPT) released its quarterly earnings data on Wednesday, October, 25th. The biotechnology company reported ($0.20) EPS for the quarter, beating the Zacks' consensus estimate of ($0.86) by $0.66. The biotechnology company earned $45.95 million during the quarter, compared to the consensus estimate of $41.29 million. Sarepta Therapeutics had a negative net margin of 112.08% and a negative return on equity of 51.72%. During the same quarter in the prior year, the firm earned ($0.95) EPS. View Sarepta Therapeutics' Earnings History.

When will Sarepta Therapeutics make its next earnings announcement?

Sarepta Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, February, 26th 2018. View Earnings Estimates for Sarepta Therapeutics.

Where is Sarepta Therapeutics' stock going? Where will Sarepta Therapeutics' stock price be in 2018?

19 Wall Street analysts have issued 12 month target prices for Sarepta Therapeutics' shares. Their forecasts range from $27.00 to $101.00. On average, they expect Sarepta Therapeutics' stock price to reach $67.11 in the next twelve months. View Analyst Ratings for Sarepta Therapeutics.

What are Wall Street analysts saying about Sarepta Therapeutics stock?

Here are some recent quotes from research analysts about Sarepta Therapeutics stock:

  • 1. According to Zacks Investment Research, "Sarepta's Exondys 51 is the first DMD treatment to gain approval in the United States. Also, a potential marketing approval in the EU should further boost sales.The company is also focused on reimbursement programs. Moreover, the company’s collaboration agreements with Summit Pharmaceuticals and Catabasis as well as its own follow-on exon-skipping pipeline candidates represent the most comprehensive approach to treat DMD. Meanwhile, the settlement of the patent litigation with BioMarin removes a major overhang for Sarepta. However, dependence on a single product, Exondys 51, is a concern. Nonetheless, Sarepta expects a pickup in patient starts and conversion rates as 2017 progresses. The company’s shares have outperformed the industry so far this year. Loss estimates have widened ahead of Q4 earnings. The company has a mixed record of earnings surprises in the recent quarters." (1/5/2018)
  • 2. Cowen Inc analysts commented, "SRPT reported 1Q17 results, including a slight Exondys 51 beat and raise; we see." (4/28/2017)
  • 3. Instinet analysts commented, "We are initiating coverage on Sarepta Therapeutics (SRPT) with a Buy rating and $84 target price. We recommend owning SRPT shares, expecting significant upside to materialize as Exondys 51 launch metrics begin to reflect an underestimated demand for the treatment and the ultimate patient numbers/market opportunity. We expect additional upside to be realized following EU approval of Exondys 51, which will help bolster perception of the drug's benefit and to define the EU opportunity, currently not reflected in shares." (3/1/2017)
  • 4. Needham & Company LLC analysts commented, "As previously reported, Sarepta earned $5.4M in 4Q16 Exondys revenue. The company gave 1Q and FY17 guidance for Exondys sales of $13-15M and >$80M, respectively. While the 1Q guidance number is relatively in line with our ($17M) and the Street's estimates, the low end of FY17 guidance is significantly below expectations and implies no acceleration in new patient starts through the back part of 2017. This sales guidance contrasts with management's qualitative commentary about accelerating conversion rates and we believe is explained by conservatism in an uncertain and dynamic reimbursement environment. We continue to expect that the majority of the 1,400+ eligible DMD boys in the US will ultimately be on therapy by implying a ~$400M Exondys US sales run rate." (3/1/2017)
  • 5. Royal Bank of Canada analysts commented, "Sarepta provided sales guidance for EXONDYS 51 on tonight's call, which clearly disappointed investors (SRPT -15%AH). We didn't hear anything on the call to justify this level of selling: while FY17 guidance appears soft to us (>$80M) and doesn't exude confidence, guidance for 1Q17 ($13-$15 vs. $5.4M in 4Q16) and management's language about conversion rate acceleration, makes us view the >$80M guidance as beatable." (3/1/2017)

Who are some of Sarepta Therapeutics' key competitors?

Who are Sarepta Therapeutics' key executives?

Sarepta Therapeutics' management team includes the folowing people:

  • Douglas S. Ingram, President, Chief Executive Officer (Age 54)
  • Sandesh Mahatme, Executive Vice President, Chief Financial Officer and Chief Business Officer (Age 52)
  • David Tyronne Howton Jr., Senior Vice President, General Counsel, Corporate Secretary (Age 45)
  • Alexander Cumbo, Senior Vice President, Global Commercial Development (Age 46)
  • Shamim Ruff, Senior Vice President - Regulatory Affairs and Quality (Age 57)
  • Catherine Stehman-Breen M.D., Senior Vice President, Chief Medical Officer (Age 54)
  • Michael W. Bonney, Director (Age 59)
  • Richard J. Barry, Independent Director (Age 58)
  • M. Kathleen Behrens Ph.D., Independent Director (Age 64)
  • Claude Nicaise M.D., Independent Director (Age 64)

Who owns Sarepta Therapeutics stock?

Sarepta Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include Schwab Charles Investment Management Inc. (0.45%), Creative Planning (0.15%), Bank of Montreal Can (0.13%), Sit Investment Associates Inc. (0.04%) and Strs Ohio (0.01%). Company insiders that own Sarepta Therapeutics stock include Alexander Cumbo, David T Howton, Douglas S Ingram, Edward M Md Kaye, Hans Lennart Rudolf Wigzell, Jayant Aphale, M Kathleen Behrens, Sandesh Mahatme and Shamim Ruff. View Institutional Ownership Trends for Sarepta Therapeutics.

Who sold Sarepta Therapeutics stock? Who is selling Sarepta Therapeutics stock?

Sarepta Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Sit Investment Associates Inc. and Creative Planning. Company insiders that have sold Sarepta Therapeutics company stock in the last year include Alexander Cumbo, Edward M Md Kaye, Hans Lennart Rudolf Wigzell, Sandesh Mahatme and Shamim Ruff. View Insider Buying and Selling for Sarepta Therapeutics.

Who bought Sarepta Therapeutics stock? Who is buying Sarepta Therapeutics stock?

Sarepta Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Schwab Charles Investment Management Inc., Strs Ohio and Bank of Montreal Can. Company insiders that have bought Sarepta Therapeutics stock in the last two years include Douglas S Ingram and M Kathleen Behrens. View Insider Buying and Selling for Sarepta Therapeutics.

How do I buy Sarepta Therapeutics stock?

Shares of Sarepta Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Sarepta Therapeutics' stock price today?

One share of Sarepta Therapeutics stock can currently be purchased for approximately $67.16.

How big of a company is Sarepta Therapeutics?

Sarepta Therapeutics has a market capitalization of $4.33 billion and generates $5.42 million in revenue each year. The biotechnology company earns $-267,260,000.00 in net income (profit) each year or ($2.04) on an earnings per share basis. Sarepta Therapeutics employs 197 workers across the globe.

How can I contact Sarepta Therapeutics?

Sarepta Therapeutics' mailing address is 215 1st St Ste 415, CAMBRIDGE, MA 02142-1213, United States. The biotechnology company can be reached via phone at +1-617-2744000 or via email at [email protected]


MarketBeat Community Rating for Sarepta Therapeutics (SRPT)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  861 (Vote Outperform)
Underperform Votes:  544 (Vote Underperform)
Total Votes:  1,405
MarketBeat's community ratings are surveys of what our community members think about Sarepta Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Sarepta Therapeutics (NASDAQ:SRPT) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.842.802.802.85
Ratings Breakdown: 0 Sell Rating(s)
3 Hold Rating(s)
16 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
16 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
16 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
15 Buy Rating(s)
1 Strong Buy Rating(s)
Consensus Price Target: $67.11$66.11$65.79$62.50
Price Target Upside: 2.22% upside18.74% upside29.66% upside54.02% upside

Sarepta Therapeutics (NASDAQ:SRPT) Consensus Price Target History

Price Target History for Sarepta Therapeutics (NASDAQ:SRPT)

Sarepta Therapeutics (NASDAQ:SRPT) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/23/2018BarclaysReiterated RatingHold$55.00LowView Rating Details
1/22/2018Royal Bank of CanadaInitiated CoverageOutperform -> OutperformHighView Rating Details
1/19/2018Leerink SwannReiterated RatingOutperform$77.00LowView Rating Details
1/9/2018HC WainwrightReiterated RatingBuy$75.00LowView Rating Details
1/3/2018Janney Montgomery ScottInitiated CoverageBuy -> Buy$75.00MediumView Rating Details
12/27/2017OppenheimerReiterated RatingBuy$76.00LowView Rating Details
10/27/2017Needham & Company LLCReiterated RatingBuyN/AView Rating Details
10/26/2017Piper Jaffray CompaniesReiterated RatingOverweightN/AView Rating Details
10/17/2017Robert W. BairdReiterated RatingBuy$101.00N/AView Rating Details
10/6/2017Goldman Sachs GroupReiterated RatingBuy -> Buy$71.00N/AView Rating Details
10/2/2017William BlairReiterated RatingOutperformLowView Rating Details
10/2/2017InstinetReiterated RatingBuy$84.00LowView Rating Details
10/2/2017Credit Suisse GroupReiterated RatingOutperform$81.00LowView Rating Details
10/2/2017Morgan StanleyUpgradeEqual Weight -> Overweight$60.00HighView Rating Details
9/25/2017JPMorgan Chase & Co.Reiterated RatingHoldLowView Rating Details
9/14/2017CowenReiterated RatingOutperform$69.00MediumView Rating Details
9/7/2017SunTrust BanksReiterated RatingBuy$56.00HighView Rating Details
9/5/2017NomuraReiterated RatingBuy$84.00LowView Rating Details
4/6/2017Jefferies GroupReiterated RatingHold$27.00MediumView Rating Details
3/1/2017JMP SecuritiesLower Price Target$48.00N/AView Rating Details
10/27/2016WedbushReiterated RatingOutperform$72.00N/AView Rating Details
9/20/2016WBB SecuritiesReiterated RatingStrong-Buy$40.00 -> $60.00N/AView Rating Details
5/5/2016Ladenburg Thalmann Financial ServicesDowngradeMarket Perform -> Underperform$13.00 -> $5.00N/AView Rating Details
(Data available from 1/23/2016 forward)

Earnings

Sarepta Therapeutics (NASDAQ:SRPT) Earnings History and Estimates Chart

Earnings by Quarter for Sarepta Therapeutics (NASDAQ:SRPT)

Sarepta Therapeutics (NASDAQ SRPT) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/26/2018($0.32)N/AView Earnings Details
10/25/2017Q3 2017($0.86)($0.20)$41.29 million$45.95 millionViewN/AView Earnings Details
7/19/2017Q2 2017($0.92)($0.46)$22.52 million$35.01 millionViewN/AView Earnings Details
4/27/2017Q1 2017($0.85)($0.73)$13.80 million$16.34 millionViewN/AView Earnings Details
2/28/2017Q416($1.33)($0.71)$4.86 million$5.42 millionViewListenView Earnings Details
10/27/2016Q316($1.32)($0.95)$1.06 millionViewListenView Earnings Details
7/19/2016Q2($1.19)($1.35)$1.10 millionViewN/AView Earnings Details
5/5/2016Q1($1.30)($1.15)$0.18 millionViewN/AView Earnings Details
2/24/2016Q4($1.18)($1.30)$1.25 millionViewN/AView Earnings Details
11/5/2015Q315($1.19)($1.25)ViewListenView Earnings Details
8/6/2015Q215($1.21)($1.01)$0.31 million$0.01 millionViewListenView Earnings Details
5/7/2015Q115($1.00)($1.49)$0.78 millionViewListenView Earnings Details
2/26/2015Q414($0.82)($0.94)$1.56 million$0.30 millionViewListenView Earnings Details
11/6/2014Q314($0.96)($0.70)$3.07 million$1.10 millionViewListenView Earnings Details
8/7/2014Q214($0.76)($0.85)$4.30 million$2.58 millionViewListenView Earnings Details
5/8/2014Q114($0.80)($0.75)$3.45 million$6.09 millionViewListenView Earnings Details
2/27/2014Q413($0.69)($0.77)$4.53 million$2.60 millionViewListenView Earnings Details
11/12/2013Q313($0.65)($0.63)$4.57 million$4.20 millionViewListenView Earnings Details
8/8/2013Q2 2013($0.67)($0.46)$5.08 million$3.00 millionViewListenView Earnings Details
5/9/2013Q1 2013($0.62)($0.41)$5.85 million$4.50 millionViewListenView Earnings Details
3/7/2013Q4 2012($0.26)($2.36)$6.71 million$7.30 millionViewListenView Earnings Details
11/7/2012($0.27)($2.17)$10.06 million$7.57 millionViewN/AView Earnings Details
8/7/2012Q2 2012($0.29)($0.24)ViewN/AView Earnings Details
5/10/2012Q1 2012($0.42)($0.30)ViewN/AView Earnings Details
3/1/2012Q4 2011($0.36)($0.06)ViewN/AView Earnings Details
11/3/2011Q3 2011($0.30)($0.18)ViewN/AView Earnings Details
8/4/2011Q2 2011($0.42)$0.05ViewN/AView Earnings Details
5/5/2011Q1 2011($0.18)$0.12ViewN/AView Earnings Details
3/10/2011Q4 2010($0.42)($0.41)ViewN/AView Earnings Details
11/9/2010Q3 2010($0.36)($0.42)ViewN/AView Earnings Details
8/9/2010Q2 2010($0.30)($0.91)ViewN/AView Earnings Details
5/10/2010Q1 2010($0.24)($0.03)ViewN/AView Earnings Details
3/16/2010Q4 2009($0.36)$0.18ViewN/AView Earnings Details
11/9/2009Q3 2009($0.42)($0.48)ViewN/AView Earnings Details
8/10/2009Q2 2009($0.12)($0.36)ViewN/AView Earnings Details
5/11/2009Q1 2009($0.18)($0.07)ViewN/AView Earnings Details
3/10/2009Q4 2008($0.30)($0.10)ViewN/AView Earnings Details
11/10/2008Q3 2008($0.42)($0.50)ViewN/AView Earnings Details
8/11/2008Q2 2008($0.42)($0.14)ViewN/AView Earnings Details
5/12/2008Q1 2008($0.78)($0.47)ViewN/AView Earnings Details
3/12/2008Q4 2007($0.45)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Sarepta Therapeutics (NASDAQ:SRPT) Earnings Estimates

2018 EPS Consensus Estimate: ($1.10)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183($0.45)($0.16)($0.35)
Q2 20183($0.49)($0.08)($0.30)
Q3 20183($0.34)($0.14)($0.24)
Q4 20183($0.22)($0.19)($0.20)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Sarepta Therapeutics (NASDAQ:SRPT)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Sarepta Therapeutics (NASDAQ SRPT) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 9.60%
Institutional Ownership Percentage: 81.97%
Insider Trades by Quarter for Sarepta Therapeutics (NASDAQ:SRPT)
Institutional Ownership by Quarter for Sarepta Therapeutics (NASDAQ:SRPT)

Sarepta Therapeutics (NASDAQ SRPT) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/30/2017Hans Lennart Rudolf WigzellDirectorSell6,667$55.89$372,618.6313,333View SEC Filing  
11/8/2017Douglas S IngramCEOBuy38,138$52.44$1,999,956.72420,196View SEC Filing  
11/6/2017Shamim RuffSVPSell10,000$55.00$550,000.0037,045View SEC Filing  
10/3/2017Shamim RuffSVPSell11,500$50.00$575,000.00View SEC Filing  
7/27/2017Douglas S IngramCEOBuy47,058$42.50$1,999,965.00382,058View SEC Filing  
7/21/2017Shamim RuffSVPSell12,138$42.97$521,569.8627,312View SEC Filing  
7/20/2017Alexander CumboSVPSell5,918$41.00$242,638.0022,793View SEC Filing  
7/20/2017Edward M Md KayeDirectorSell10,000$41.00$410,000.0062,471View SEC Filing  
7/20/2017Sandesh MahatmeCFOSell50,000$41.00$2,050,000.0041,736View SEC Filing  
10/17/2016Sandesh MahatmeInsiderSell30,000$50.08$1,502,400.0061,532View SEC Filing  
9/22/2016David T HowtonSVPSell7,000$60.00$420,000.0028,453View SEC Filing  
9/22/2016Edward M Md KayeCEOSell40,179$60.00$2,410,740.00117,162View SEC Filing  
9/19/2016David T HowtonSVPSell9,304$50.00$465,200.0011,168View SEC Filing  
9/19/2016Edward M Md KayeCEOSell24,352$50.00$1,217,600.0089,983View SEC Filing  
9/19/2016Jayant AphaleVPSell35,000$50.00$1,750,000.0021,490View SEC Filing  
9/14/2016Edward M Md KayeCEOSell24,557$30.00$736,710.0076,983View SEC Filing  
3/16/2016M Kathleen BehrensDirectorBuy10,000$14.54$145,400.00112,166View SEC Filing  
3/14/2016M Kathleen BehrensDirectorBuy65,000$16.54$1,075,100.00112,166View SEC Filing  
11/14/2013Anthony ChaseDirectorBuy10,000$13.95$139,500.0041,744View SEC Filing  
9/16/2013M Kathleen BehrensDirectorBuy6,500$37.04$240,760.0044,166View SEC Filing  
9/3/2013John HodgmanDirectorSell5,556$34.97$194,293.32View SEC Filing  
8/22/2013Anthony ChaseDirectorBuy3,500$32.68$114,380.0031,744View SEC Filing  
8/20/2013Sandesh MahatmeCFOBuy5,000$31.10$155,500.005,000View SEC Filing  
6/14/2013Anthony R ChaseDirectorBuy10,000$38.50$385,000.00View SEC Filing  
9/7/2012M Kathleen BehrensDirectorBuy17,500$14.73$257,775.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Sarepta Therapeutics (NASDAQ SRPT) News Headlines

Source:
DateHeadline
In This Booming Stock Market, Think Like a Programmer Not a CriticIn This Booming Stock Market, Think Like a Programmer Not a Critic
finance.yahoo.com - January 22 at 3:43 PM
Sarepta Therapeutics Inc Expected to Earn FY2020 Earnings of $2.91 Per Share (SRPT)Sarepta Therapeutics Inc Expected to Earn FY2020 Earnings of $2.91 Per Share (SRPT)
www.americanbankingnews.com - January 22 at 2:52 PM
Sarepta Therapeutics (SRPT) Rating Reiterated by Leerink SwannSarepta Therapeutics (SRPT) Rating Reiterated by Leerink Swann
www.americanbankingnews.com - January 20 at 4:08 PM
First Duchenne Muscular Dystrophy Patient Dosed in Systemic Microdystrophin Gene TherapyFirst Duchenne Muscular Dystrophy Patient Dosed in Systemic Microdystrophin Gene Therapy
www.prnewswire.com - January 17 at 3:33 PM
Sarepta: Rosy Prospects Continue, Buying On Dips - Seeking AlphaSarepta: Rosy Prospects Continue, Buying On Dips - Seeking Alpha
seekingalpha.com - January 15 at 3:33 PM
Sarepta Therapeutics Sees Unusually High Options Volume (SRPT)Sarepta Therapeutics Sees Unusually High Options Volume (SRPT)
www.americanbankingnews.com - January 15 at 6:16 AM
Sarepta Therapeutics (SRPT) Upgraded at BidaskClubSarepta Therapeutics (SRPT) Upgraded at BidaskClub
www.americanbankingnews.com - January 13 at 12:28 PM
You Cant Reason With a SteamrollerYou Can't Reason With a Steamroller
finance.yahoo.com - January 12 at 3:31 PM
Sarepta is making a bold bet on genetic medicineSarepta is making a bold bet on genetic medicine
finance.yahoo.com - January 10 at 3:33 PM
Sarepta Therapeutics: Continued Upside In 2018 - Seeking AlphaSarepta Therapeutics: Continued Upside In 2018 - Seeking Alpha
seekingalpha.com - January 10 at 11:37 AM
Sarepta Therapeutics (SRPT) Buy Rating Reiterated at HC WainwrightSarepta Therapeutics' (SRPT) Buy Rating Reiterated at HC Wainwright
www.americanbankingnews.com - January 9 at 12:50 PM
Sarepta Therapeutics Pre-Announces Fourth Quarter 2017 Revenue and Provides Full-Year 2018 RevenueSarepta Therapeutics Pre-Announces Fourth Quarter 2017 Revenue and Provides Full-Year 2018 Revenue
www.nasdaq.com - January 8 at 4:07 PM
Sarepta Therapeutics (SRPT) Sees Q4 Revenue of $57.3M, Modestly Above the Street - StreetInsider.comSarepta Therapeutics (SRPT) Sees Q4 Revenue of $57.3M, Modestly Above the Street - StreetInsider.com
www.streetinsider.com - January 8 at 3:38 PM
Sarepta Therapeutics Pre-Announces Fourth Quarter 2017 Revenue and Provides Full-Year 2018 Revenue Guidance for EXONDYS 51® (eteplirsen), Representing Approximately 100 Percent Year-over-Year GrowthSarepta Therapeutics Pre-Announces Fourth Quarter 2017 Revenue and Provides Full-Year 2018 Revenue Guidance for EXONDYS 51® (eteplirsen), Representing Approximately 100 Percent Year-over-Year Growth
finance.yahoo.com - January 8 at 3:38 PM
Sarepta Therapeutics Inc (SRPT) Receives Average Recommendation of "Buy" from BrokeragesSarepta Therapeutics Inc (SRPT) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - January 8 at 2:44 PM
Today’s Research Reports on Stocks to Watch: Sarepta Therapeutics and Valeant PharmaceuticalsToday’s Research Reports on Stocks to Watch: Sarepta Therapeutics and Valeant Pharmaceuticals
finance.yahoo.com - January 8 at 9:20 AM
Q1 2018 Earnings Estimate for Sarepta Therapeutics Inc (SRPT) Issued By Leerink SwannQ1 2018 Earnings Estimate for Sarepta Therapeutics Inc (SRPT) Issued By Leerink Swann
www.americanbankingnews.com - January 8 at 4:38 AM
BidaskClub Lowers Sarepta Therapeutics (SRPT) to HoldBidaskClub Lowers Sarepta Therapeutics (SRPT) to Hold
www.americanbankingnews.com - January 6 at 3:38 PM
Sarepta Therapeutics, Inc. (SRPT)Sarepta Therapeutics, Inc. (SRPT)
finance.yahoo.com - January 6 at 3:34 PM
Zacks Investment Research Lowers Sarepta Therapeutics (SRPT) to SellZacks Investment Research Lowers Sarepta Therapeutics (SRPT) to Sell
www.americanbankingnews.com - January 5 at 2:32 PM
Equities Analysts Offer Predictions for Sarepta Therapeutics Incs Q2 2018 Earnings (SRPT)Equities Analysts Offer Predictions for Sarepta Therapeutics Inc's Q2 2018 Earnings (SRPT)
www.americanbankingnews.com - January 5 at 12:06 PM
Sarepta Therapeutics Inc (SRPT) Expected to Post Quarterly Sales of $55.78 MillionSarepta Therapeutics Inc (SRPT) Expected to Post Quarterly Sales of $55.78 Million
www.americanbankingnews.com - January 4 at 5:04 PM
Sarepta Therapeutics (SRPT) Research Coverage Started at Janney Montgomery ScottSarepta Therapeutics (SRPT) Research Coverage Started at Janney Montgomery Scott
www.americanbankingnews.com - January 3 at 6:24 PM
Sarepta Therapeutics: A Top 2018 Pick - Seeking AlphaSarepta Therapeutics: A Top 2018 Pick - Seeking Alpha
seekingalpha.com - January 3 at 10:57 AM
Sarepta Therapeutics Inc (SRPT) Expected to Post Earnings of -$0.36 Per ShareSarepta Therapeutics Inc (SRPT) Expected to Post Earnings of -$0.36 Per Share
www.americanbankingnews.com - January 2 at 1:06 AM
Q4 2017 EPS Estimates for Sarepta Therapeutics Inc Decreased by Oppenheimer (SRPT)Q4 2017 EPS Estimates for Sarepta Therapeutics Inc Decreased by Oppenheimer (SRPT)
www.americanbankingnews.com - December 29 at 7:58 AM
Sarepta Therapeutics (SRPT) Stock Rating Reaffirmed by OppenheimerSarepta Therapeutics (SRPT) Stock Rating Reaffirmed by Oppenheimer
www.americanbankingnews.com - December 27 at 3:16 PM
Encore! Encore! Why Sarepta Can Keep On Keeping On After 2017 DoubleEncore! Encore! Why Sarepta Can Keep On Keeping On After 2017 Double
finance.yahoo.com - December 27 at 1:29 PM
UBS Group Reaffirms "Outperform" Rating for Sarepta Therapeutics (SRPT)UBS Group Reaffirms "Outperform" Rating for Sarepta Therapeutics (SRPT)
www.americanbankingnews.com - December 27 at 9:53 AM
Sarepta Therapeutics (SRPT) Reports Publication of Long-Term Pulmonary Function of Eteplirsen-Treated Patients ... - StreetInsider.comSarepta Therapeutics (SRPT) Reports Publication of Long-Term Pulmonary Function of Eteplirsen-Treated Patients ... - StreetInsider.com
www.streetinsider.com - December 27 at 8:52 AM
Sarepta Therapeutics Announces Publication of Long-Term Pulmonary Function of Eteplirsen-Treated Patients Compared to Natural History of Duchenne Muscular Dystrophy in The Journal of Neuromuscular DiseasesSarepta Therapeutics Announces Publication of Long-Term Pulmonary Function of Eteplirsen-Treated Patients Compared to Natural History of Duchenne Muscular Dystrophy in The Journal of Neuromuscular Diseases
finance.yahoo.com - December 27 at 8:52 AM
[$$] Susquehanna: 3 Microcap Stocks Its Buying and 1 Mid-Cap[$$] Susquehanna: 3 Microcap Stocks It's Buying and 1 Mid-Cap
finance.yahoo.com - December 22 at 4:11 PM
First Week of SRPT August 2018 Options TradingFirst Week of SRPT August 2018 Options Trading
www.nasdaq.com - December 21 at 3:37 PM
Notable ETF Outflow Detected - XBI, SRPT, NBIX, UTHR - NasdaqNotable ETF Outflow Detected - XBI, SRPT, NBIX, UTHR - Nasdaq
www.nasdaq.com - December 19 at 3:32 PM
Sarepta Therapeutics, Inc. – Value Analysis (NASDAQ:SRPT) : December 19, 2017Sarepta Therapeutics, Inc. – Value Analysis (NASDAQ:SRPT) : December 19, 2017
finance.yahoo.com - December 19 at 3:32 PM
Sarepta Therapeutics (SRPT) Lowered to Hold at BidaskClubSarepta Therapeutics (SRPT) Lowered to Hold at BidaskClub
www.americanbankingnews.com - December 19 at 6:04 AM
Sarepta Therapeutics Inc (SRPT) Expected to Post Quarterly Sales of $56.22 MillionSarepta Therapeutics Inc (SRPT) Expected to Post Quarterly Sales of $56.22 Million
www.americanbankingnews.com - December 18 at 5:32 PM
Sarepta Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : SRPT-US : December 18, 2017Sarepta Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : SRPT-US : December 18, 2017
finance.yahoo.com - December 18 at 10:38 AM
-$0.35 Earnings Per Share Expected for Sarepta Therapeutics Inc (SRPT) This Quarter-$0.35 Earnings Per Share Expected for Sarepta Therapeutics Inc (SRPT) This Quarter
www.americanbankingnews.com - December 16 at 9:30 AM
Sarepta Therapeutics (SRPT) Downgraded by Zacks Investment ResearchSarepta Therapeutics (SRPT) Downgraded by Zacks Investment Research
www.americanbankingnews.com - December 15 at 1:36 PM
Sarepta Therapeutics Inc (SRPT) Given Average Rating of "Buy" by BrokeragesSarepta Therapeutics Inc (SRPT) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - December 14 at 6:02 PM
Here's What Caused Sarepta Therapeutics to Shoot 13% Higher In NovemberHere's What Caused Sarepta Therapeutics to Shoot 13% Higher In November
finance.yahoo.com - December 7 at 11:02 AM
Sarepta Therapeutics Elects Biopharmaceutical Veteran, Michael W. Bonney, to its Board of DirectorsSarepta Therapeutics Elects Biopharmaceutical Veteran, Michael W. Bonney, to its Board of Directors
finance.yahoo.com - December 5 at 12:41 PM
Notable ETF Inflow Detected - XBI, ALNY, JUNO, SRPT - NasdaqNotable ETF Inflow Detected - XBI, ALNY, JUNO, SRPT - Nasdaq
www.nasdaq.com - December 5 at 11:28 AM
Heres Why Sarepta Stock is Up More Than 70% in 6 Months - NasdaqHere's Why Sarepta Stock is Up More Than 70% in 6 Months - Nasdaq
www.nasdaq.com - December 5 at 11:28 AM
Sarepta Therapeutics Elects Biopharmaceutical Veteran, Michael W. Bonney, to its Board of Directors - GlobeNewswire (press release)Sarepta Therapeutics Elects Biopharmaceutical Veteran, Michael W. Bonney, to its Board of Directors - GlobeNewswire (press release)
globenewswire.com - December 5 at 11:28 AM
Sarepta Therapeutics Inc (SRPT) Director Hans Lennart Rudolf Wigzell Sells 6,667 SharesSarepta Therapeutics Inc (SRPT) Director Hans Lennart Rudolf Wigzell Sells 6,667 Shares
www.americanbankingnews.com - December 4 at 9:02 PM
Sarepta Therapeutics (SRPT) Receives New Coverage from Analysts at HC WainwrightSarepta Therapeutics (SRPT) Receives New Coverage from Analysts at HC Wainwright
www.americanbankingnews.com - December 1 at 8:10 AM
Sarepta Therapeutics Inc (SRPT) Expected to Announce Quarterly Sales of $55.98 MillionSarepta Therapeutics Inc (SRPT) Expected to Announce Quarterly Sales of $55.98 Million
www.americanbankingnews.com - November 30 at 10:28 PM
Contrasting Sarepta Therapeutics (SRPT) and Its CompetitorsContrasting Sarepta Therapeutics (SRPT) and Its Competitors
www.americanbankingnews.com - November 28 at 5:20 PM

SEC Filings

Sarepta Therapeutics (NASDAQ:SRPT) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Sarepta Therapeutics (NASDAQ:SRPT) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Sarepta Therapeutics (NASDAQ SRPT) Stock Chart for Tuesday, January, 23, 2018

Loading chart…

This page was last updated on 1/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.